Core Viewpoint - Franco-Nevada Corporation has announced a significant financing package of A$220 million (approximately $155 million) with Minerals 260 to support the development of the Bullabulling Gold Project in Western Australia, marking Franco-Nevada's largest royalty acquisition in Australia [1] Group 1: Transaction Details - Franco-Nevada will acquire a gross royalty of A$170 million (approximately $120 million) from Minerals 260, increasing its total gross royalty on the Bullabulling land package to 2.45% [1] - The financing package includes a subscription for A$50 million (approximately $35 million) of Minerals 260's ordinary shares, resulting in Franco-Nevada owning approximately 4.9% of Minerals 260's issued shares [1][2] - The initial A$75 million royalty funding is expected to occur around February 26, 2026, with a second A$95 million funding contingent on obtaining FIRB approval [2] Group 2: Project Overview - The Bullabulling Gold Project is located approximately 65 km from Kalgoorlie, Western Australia, with existing resources of 3.0 million ounces (Moz) of Indicated Resources and 1.5 Moz of Inferred Resources [1] - The project has significant exploration potential, with a large resource base covering multiple deposits and a recent drilling campaign that nearly doubled the mineral resources since 2011 [1] - A pre-feasibility study is targeted for completion by mid-2026, with a final investment decision expected in early 2027, and first gold production potentially as soon as the second half of 2028 [1] Group 3: Management and Expertise - Minerals 260 is led by experienced management, including Chairman Tim Goyder, who has over 40 years in the resource industry, and CEO Luke McFadyen, who has over 15 years of mining experience [1] - The management team's expertise is expected to facilitate the rapid advancement of the Bullabulling project and unlock value for shareholders [1]

The platform integrates Wonder Cognitiveâ"¢- proprietary Cognitive Twin technology with real-time clinical escalation pathways designed to address the growing safety crisis in AI mental health LOS ANGELES, Feb. 22, 2026 /PRNewswire/ -- VIVE Conference — Wonder Sciences today announced the pilot launch of WonderMate, an AI digital therapist and clinical co-pilot built from inception around established therapeutic frameworks, longitudinal cognitive modeling, and human-led safety escalation. Pilot sign-ups are ...

Decker to Make Official Debut with Team Venturi at Atlanta Motor Speedway on July 11 ATLANTA, Feb. 22, 2026 /PRNewswire/ -- Venturi Bold Brew, the performance-driven coffee brand redefining premium energy, proudly announces a new partnership with NASCAR driver Natalie Decker. Decker will make her first official appearance as a driver for Team Venturi at the highly anticipated July 11th race in Atlanta, Georgia. This partnership signals a bold new chapter for both Venturi Bold Brew and Natalie Decker uniting ...

Core Viewpoint - A securities fraud class action lawsuit has been filed against Oracle Corporation, alleging material misstatements regarding its data center capabilities for AI infrastructure and capital expenditures during the class period from June 12, 2025, to December 16, 2025 [1] Summary by Relevant Sections Lawsuit Details - The lawsuit, titled Barrows v. Oracle Corporation, was filed on February 3, 2026, in the United States District Court for the District of Delaware [1] - Investors who purchased Oracle common stock during the class period may seek to serve as lead plaintiff by April 6, 2026 [1] Allegations - The complaint alleges that Oracle misled investors by overstating its contracts for AI infrastructure development and falsely assuring that significant capital expenditures would lead to rapid revenue growth [1] - Specific allegations include: 1. Oracle's AI infrastructure strategy would lead to substantial increases in capital expenditures without corresponding near-term revenue growth [1] 2. Increased spending posed risks to Oracle's debt, credit rating, free cash flow, and project funding [1] 3. Defendants' statements regarding Oracle's business and prospects were materially false and misleading [1] Investor Actions - Investors are encouraged to retain legal counsel or contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation [1] - The lead plaintiff process allows investors to represent the class and direct the litigation, with the deadline for filing set for April 6, 2026 [1]

Core Insights - Princess Cruises celebrated National Margarita Day by breaking the GUINNESS WORLD RECORDS™ title for the Most Margaritas Sold in 8 Hours, selling 3,410 handcrafted 24K Margaritas, surpassing the previous record of 2,728 [1] - The event took place aboard the Regal Princess during a 7-day Western Caribbean cruise, marking the sale of over 1 million 24K Margaritas since the partnership with Pantalones Organic Tequila began in October 2024 [1] Group 1: Record Achievement - The record-setting event occurred on February 17, 2026, while the Regal Princess was docked in Cozumel [1] - The achievement was recognized by Thomas Bradford, an Official Adjudicator from Guinness World Records, highlighting the celebratory atmosphere on the ship [1] Group 2: Sales Milestone - From January 1, 2025, to January 7, 2026, Princess Cruises sold a total of 1,038,197 24K Margaritas, solidifying its status as the fleet's most popular signature cocktail [1] - The 24K Margarita is made exclusively with Pantalones Organic Blanco Tequila and has become a must-sip experience across the Princess fleet [1] Group 3: Partnership and Product Details - The collaboration with Pantalones Organic Tequila has been described as one of the most successful beverage partnerships in cruise line history [1] - Pantalones Organic Tequila is available in various expressions, including Blanco, Reposado, and Añejo, and is featured in a lineup of handcrafted cocktails created with Princess Mixologist Rob Floyd [1][2] Group 4: Celebrity Involvement - Co-founders Camila and Matthew McConaughey sent a congratulatory video message, celebrating the historic achievement and the spirit of joy associated with the brand [1] - The couple also participated in the recent christening of Princess' newest ship, Star Princess, further enhancing the brand's visibility and appeal [1]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of DNOW Inc. due to allegations of materially misleading business information issued by the company [1] Financial Performance - DNOW Inc. reported disappointing fourth-quarter 2025 financial results, which included a significant loss and missed Wall Street's expectations [1] - Following the announcement of these results, DNOW stock fell by 19.1% on February 20, 2026 [1] Legal Action - Investors who purchased DNOW Inc. securities may be entitled to compensation through a contingency fee arrangement without any out-of-pocket costs [1] - Rosen Law Firm is preparing a class action to seek recovery of investor losses [1] Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company [1] - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013 [1] - In 2019, the firm secured over $438 million for investors [1]

Core Points - The Rosen Law Firm is reminding investors who purchased CoreWeave, Inc. securities between March 28, 2025, and December 15, 2025, of a lead plaintiff deadline on March 13, 2026 [1] - Investors may be entitled to compensation through a contingency fee arrangement without any out-of-pocket costs [1] - A class action lawsuit has been filed against CoreWeave, alleging that the company made false and misleading statements regarding its ability to meet customer demand and the risks associated with reliance on a single third-party data center supplier [1] Legal Context - The lawsuit claims that CoreWeave overstated its capacity to meet customer demand and understated the risks related to its data center supplier, which could negatively impact revenue [1] - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions [1] - The Rosen Law Firm has a history of significant settlements in securities class actions, including a record settlement against a Chinese company [1]

Core Points - CoreWeave, Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934 during the class period from March 28, 2025, to December 15, 2025 [1] - The lawsuit claims that CoreWeave and its executives made misleading statements regarding the company's ability to meet customer demand and the risks associated with reliance on a single third-party data center supplier [1] - Significant events leading to the lawsuit include a failed merger with Core Scientific, which caused a share price drop of over 6%, and a subsequent revenue guidance reduction that led to a further decline of more than 16% in share price [1] Company Overview - CoreWeave is positioned as an AI cloud computing company and had announced a deal worth up to $11.9 billion with OpenAI shortly before its IPO [1] - The company also attempted to acquire Core Scientific, a major player in digital infrastructure for high-performance computing, in an all-stock transaction [1] Allegations and Impact - The lawsuit alleges that CoreWeave overstated its service capabilities and downplayed the risks associated with its data center supplier, which were likely to negatively impact revenue [1] - On October 30, 2025, Core Scientific announced it did not have enough shareholder votes to approve the merger with CoreWeave, leading to a significant drop in CoreWeave's stock price [1] - Following a revenue guidance cut on November 10, 2025, due to delays from a third-party data center developer, CoreWeave's CEO acknowledged that multiple data centers were affected, resulting in a further stock price decline [1] - A December 15, 2025, article from The Wall Street Journal revealed more severe data center delivery issues than previously disclosed, causing an additional 3.4% drop in share price [1]

Group 1 - Phemex has completed the full integration of Ondo Finance's tokenized equity suite, positioning itself as a leader in the Real-World Asset (RWA) revolution [1] - The platform now offers its 10 million global users seamless access to a diverse selection of 14 traditional blue-chip assets in tokenized form, including major companies like NVIDIA, Tesla, Apple, and Amazon [1] - This strategic initiative emphasizes Phemex's commitment to accelerating the convergence of Traditional Finance (TradFi) and Web3, enhancing capital efficiency and portfolio diversification for users [1] Group 2 - Phemex, founded in 2019, is a user-centric cryptocurrency platform trusted by over 10 million traders worldwide, offering spot and derivatives trading, copy trading, and asset management products [1] - The platform aims to provide reliable tools, inclusive access, and evolving opportunities for traders at all levels, prioritizing user experience, transparency, and innovation [1]

Core Insights - Johnson & Johnson announced long-term data from the QUASAR study showing that TREMFYA® (guselkumab) maintains clinical and endoscopic remission in ulcerative colitis patients over three years, with over 80% of patients in clinical remission and more than 50% in endoscopic remission at Week 140 [1][2]. Group 1: Clinical Efficacy - At Week 140, 80.8% of patients treated with TREMFYA® were in clinical remission, while 53.6% achieved endoscopic remission [1]. - 78.6% of patients experienced histo-endoscopic mucosal improvement (HEMI), indicating significant intestinal healing [1]. - Among those in clinical remission at Week 44, 87.5% maintained remission through Week 140, demonstrating sustained efficacy [1]. Group 2: Study Retention and Safety - Approximately 89% of eligible study participants completed treatment through Week 140, indicating high retention rates [1]. - No new safety concerns were reported during the study, reinforcing the long-term safety profile of TREMFYA® [1][2]. Group 3: Mechanism and Approval - TREMFYA® is the first and only approved dual-acting monoclonal antibody that blocks IL-23 and binds to CD64, targeting immune-mediated diseases [1][2]. - The drug has received FDA and European Commission approval for treating both moderately to severely active Crohn's disease and ulcerative colitis [1][2]. Group 4: Additional Research and Commitment - Johnson & Johnson presented 30 abstracts at the European Crohn's and Colitis Organisation (ECCO) 2026 conference, highlighting ongoing research and commitment to inflammatory bowel disease treatments [1]. - Two other abstracts from Johnson & Johnson were recognized as Top 10 oral abstracts, showcasing the company's dedication to advancing treatment options [1].